Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors

Journal of Oncology Pharmacy Practice

Volumn 11, Issue 2, 2005, Pages 37-43

  McCune, Jeannine S ^a   Games, Dona M ^a,b   Espirito, Janet L ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c NONE

Author keywords

Breast cancer; Chemotherapy induced amenorrhoea; Osteoporosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; FEMALE; HUMAN; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MEDICAL RECORD; MENSTRUAL CYCLE; MENSTRUATION DISORDER; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; RELIABILITY; RETROSPECTIVE STUDY; SCREENING TEST; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BREAST NEOPLASMS; CALCIUM; CONTRACEPTIVES, ORAL; CYCLOPHOSPHAMIDE; DENSITOMETRY, X-RAY; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; ESTRADIOL; FEMALE; FLUOROURACIL; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; MEDICAL RECORDS; MENSTRUATION DISTURBANCES; METHOTREXATE; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIAN FAILURE, PREMATURE; PREMENOPAUSE; PROCESS ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SURVIVORS; TAMOXIFEN; TIME FACTORS;

EID: 23644440998     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155205jp144oa     Document Type: Article

References (42)

1. Smart CR, Byrne C, Smith RA, et al. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1997; 47: 134-49.
2. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365-70.
3. Fornier MN, Modi S, Hudis CA. Incidence of amenorrhea in breast cancer patients <40 years of age after paclitaxel-based adjuvant chemotherapy. Paper presented at: San Antonio Breast Cancer Symposia, 2002; San Antonio, TX.
4. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.
5. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718-729.
6. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001; 19: 3306-311.
7. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis, Volume 843. Geneva: WHO, 1994.
8. Diet IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63.
9. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-224.
10. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19: 10-17.
11. Pfeilschifter J, Diet IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570-93.
12. Lata PF, Binkley NC, Elliott ME. Acceptability of pharmacy-based bone density measurement by women and primary healthcare providers. Menopause 2002; 9: 449-55.
13. Elliott ME, Meek PD, Kanous NL, et al. Osteoporosis screening by community pharmacists: use of National Osteoporosis Foundation resources. J Am Pharm Assoc (Wash) 2002; 42: 101-10; quiz 110-11.
14. Wu F, Mason B, Horne A, et al. Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures. Arch Intern Med 2002; 162: 33-36.
15. Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002; 20: 3637-643.
16. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-869.
17. Cooper RG, Holland JF, Glidewell O. Adjuvant chemotherapy of breast cancer. Cancer 1979; 44: 793-98.
18. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-42.
19. Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Long-term sequelae from adjuvant chemotherapy. Recent Results Cancer Res 1993; 127: 247-55.
20. Cobleigh MA, Bines J, Harris D. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Proc ASCO 1995; 14: 158A.
21. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84.
22. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments]. J Natl Cancer Inst 1998; 90: 1371-388.
23. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997; 43: 183-90.
24. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34: 632-40.
25. Poikonen P, Saarto T, Elomaa I, Joensuu H, Blomqvist C. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer 2000; 36: 43-48.
26. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003, 21: 4184-193.
27. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002; 13: 138-47.
28. Pereyra Pacheco B, Mendez Ribas JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001; 81: 391-97.
29. Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA 2001; 286: 1490-493.
30. Aisenberg J, Hsieh K, Kalaitzoglou G, et al. Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol 1998; 20: 241-45.
31. Stuart-Harris RC, Harper PG, Parsons CA, et al. High-dose alkylation therapy using ifostamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1983; 11: 69-72.
32. Gilsanz V, Carlson ME, Roe TF, Ortega JA. Osteoporosis after cranial irradiation for acute lymphoblastic leukemia. J Pediatr 1990; 117: 238-44.
33. Nysom K, Holm K, Fleischer Michaelsen K, Hertz H, Muller J, Molgaard C. Bone mass after treatment of malignant lymphoma in childhood. Med Pediatr Oncol 2001; 37: 518-24.
34. Arikoski P, Komulainen J, Voutilainen R, et al. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998; 20: 234-40.
35. Kaste SC, Jones-Wallace D, Rose SR, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15: 728-34.
36. Laufer MR. Reproductive issues for cancer patients/survivors. J Clin Oncol 1999; 17: 2631-632.
37. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 1341-347.
38. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-57.
39. Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 2003; 30: 763-75.
40. Physician's guide to the prevention and treatment of osteoporosis. National Osteoporosis Foundation. Retrieved 22 October, 2003, from: http://www.nof.org/physguide/index.htm
41. Rosenthal WM. Implementing bone mineral density testing in the community pharmacy. J Am Pharm Assoc (Wash) 2000; 40: 737-45.
42. Rolnick SJ, Kopher R, Jackson J, Fischer LR, Compo R. What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? Menopause 2001; 8: 141-48.